P&T Portfolio: Vitrase (hyaluronidase for injection)

Results show consistent improvements in wakefulness, cataplexy, and quality of life with oveporexton for patients with narcolepsy.

Researchers assess the differences in out-of-pocket spending on brand name compared with generic medication.

Practical takeaways to improve real‑world clinic outcomes for PAINWeek 2026.

Starting with Exelixis’ condition on in-house dispensing data, manufacturers are introducing a new approach to 340B claims focused on transparency.

The trial found that up to 25 days of nirmatrelvir-ritonavir did not improve cognitive, autonomic, or exercise-related symptoms compared with placebo.

Digital innovation and proactive patient care are converging to transform clinical practice while preserving essential safeguards.

James Barnes, CPhT, explains why respecting a patient's time isn't about speed and how he landed in the pharmacy by chance.

ACIP changes, new court rulings, and coverage gaps threaten vaccines, pharmacists’ reimbursement, and children's access through Vaccine For Children.